Ocugen, Inc. OCGN
Set alert
At close · Oct 30
After hours · Oct 30, 7:56 PM ET
- YTD
- -47.95%
- 1 year
- -52.52%
- Open
- 0.746
- Prev close
- 0.7442
- Mkt cap
- 238.29M
- Vol
- 5.42M
- Avg vol
- 6.48M
- EPS
- -0.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6909
- High
- 0.76
- Forward P/E
- -2.85
- Beta
- 3.77
- Short ratio
- 14.01
- Inst. own
- 27.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.92278
- 200-d avg
- 1.30
- 1y target
- 6.25
MAX chart
Events in this range
- May 5, 2023Earnings: -0.07; estimate -0.11; surprise 36.36%
Signals (29)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 1 day ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| SMA: Bullish | Jun 1, 2025 | 1 year ago |
| SMA: Bullish | Jun 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | May 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bearish | Jan 1, 2022 | 4 years ago |
| SMA: Bearish | Nov 1, 2021 | 5 years ago |
| SMA: Bullish | Oct 1, 2021 | 5 years ago |
| SMA: Bearish | Sep 1, 2021 | 5 years ago |
| SMA: Bullish | Feb 1, 2021 | 5 years ago |
| SMA: Bullish | Dec 1, 2020 | 5 years ago |
| SMA: Bearish | Aug 1, 2020 | 6 years ago |
| SMA: Bullish | Jul 1, 2020 | 6 years ago |
| SMA: Bearish | Sep 1, 2019 | 7 years ago |
| SMA: Bullish | Aug 1, 2019 | 7 years ago |
| MACD: Buy Signal | Aug 1, 2019 | 7 years ago |
| MACD: Sell Signal | Nov 1, 2018 | 8 years ago |
| SMA: Bearish | Sep 1, 2018 | 8 years ago |
| SMA: Bearish | Sep 1, 2018 | 8 years ago |
| SMA: Bullish | Aug 1, 2018 | 8 years ago |
| SMA: Bearish | Jul 1, 2018 | 8 years ago |
| SMA: Bullish | Jan 1, 2018 | 8 years ago |
| SMA: Bullish | Jul 1, 2017 | 9 years ago |
| SMA: Bearish | Nov 1, 2016 | 10 years ago |
| RSI: Oversold | Nov 1, 2016 | 10 years ago |
| SMA: Bullish | Aug 1, 2016 | 10 years ago |
Key statistics
- Market cap
- 215.61M
- Enterprise value
- 190.98M
- Trailing P/E
- 0.00
- Forward P/E
- -2.85
- PEG ratio
- 0.00
- Price / sales
- 45.87
- Price / book
- 4.68
- EPS (TTM)
- -0.19
- Beta
- 3.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.70M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 38.70M
- Total debt
- 6.78M
- Return on equity
- -103.29%
- Shares outstanding
- 291.32M
- Short % of float
- 19.90%
- 50-day average
- 0.92278
- 200-day average
- 1.30
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 6.25
- Target (high)
- 8.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.05667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2024 | Jun 1, 2024 | -0.06 | -0.04 | +0.02 | +33.33% |
| May 14, 2024 | Mar 1, 2024 | -0.06 | -0.05 | +0.01 | +16.67% |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | -0.04 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.08 | -0.06 | +0.02 | +25.00% |
| Aug 21, 2023 | Jun 1, 2023 | -0.08 | -0.10 | -0.02 | -25.00% |
| May 5, 2023 | Mar 1, 2023 | -0.11 | -0.07 | +0.04 | +36.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 15, 2024 | Maxim Group | init | — | Buy |
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ocugen.com
News
- Ocugen to Participate in Upcoming November Investor and Industry Conferences
- Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
- Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region
- Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
- Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
- Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
- Transcript: Ocugen Q2 2026 Earnings Conference Call
- Ocugen to Participate in Upcoming Scientific Conferences
- Ocugen to Participate in Upcoming October Investor and Industry Conferences
Your note
Sign in to keep a note on OCGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASTILLO KIRSTEN M | Director | Purchase | Nov 21, 2024 | 75,000 |
| CRESPO JESSICA | Officer | Stock Award(Grant) | Jan 2, 2023 | 163,391 |
| FERNANDES PRABHAVATHI | Director | Purchase | Nov 25, 2024 | 10,000 |
| MUSUNURI SHANKAR PH.D | Chief Executive Officer | Sale | Feb 15, 2023 | 3,335,370 |
| UPADHYAY ARUN | Officer | Stock Award(Grant) | Jan 2, 2023 | 400,083 |
| ZHANG JUNGE | Director | Purchase | Jun 13, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.39% | 18,614,758 | 13.78M | Sep 29, 2024 |
| Vanguard Group Inc | 5.82% | 16,949,019 | 12.54M | Sep 29, 2024 |
| State Street Corporation | 5.43% | 15,824,517 | 11.71M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.16% | 6,278,554 | 4.65M | Sep 29, 2024 |
| GMT Capital Corp | 0.84% | 2,454,958 | 1.82M | Sep 29, 2024 |
| Altium Capital Management, LP | 0.81% | 2,350,000 | 1.74M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.15% | 9,164,955 | 6.78M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.11% | 9,074,589 | 6.72M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.28% | 6,653,124 | 4.92M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.41% | 4,095,054 | 3.03M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.90% | 2,632,960 | 1.95M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.78% | 2,284,595 | 1.69M | Oct 30, 2024 |